News and Announcements
Australian Patent Granted for Use of Midkine for Hair Growth
- Published January 13, 2015 1:49PM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Source: ASX; Published: Sydney, 12th January 2015
Cellmid Limited (ASX:CDY) has received official Notice of Acceptance from IP Australia for Cellmid’s patent application 2011220326.
This patent protects the use of midkine and the closely related protein pleiotrophin for use as a hair loss and/or hair growth treatments. The granted claims cover topical formulations of all kinds, including shampoos, conditioners,creams and lotions with protection until 2031.
This patent family adds to the already considerable intellectual property assets of Cellmid’s wholly owned anti-aging hair growth subsidiary, Advagen, which include patent protection and extensive know-how around its FGF5 inhabiting technologies, cell based assays, formulations and brands.
To read the full announcement please download the document below.